Article Contents ::

Details About Generic Salt ::  Eprosart

Main Medicine Class:: Antihypertensive, Angiotensin II antagonist   

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

 

Drugs Class ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Indications for Drugs ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Drug Dose ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Contraindication ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Drug Precautions ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Drug Side Effects ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Drug Mode of Action ::  

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Drug Interactions ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

Drug Assesment ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Drug Storage/Management ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Drug Notes ::

(eh-pro-SAHR-tan MAL-ee-ate)
Teveten
Tablets: 400 mg
Tablets: 600 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II receptor (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 400 to 800 mg/day; usual starting dose 600 mg/day.

 

 Interactions None well documented.

 

 Lab Test Interferences

Lithium

Plasma concentrations may be increased by eprosartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Adverse Reactions

CARDIOVASCULAR: Abnormal ECG; extrasystoles; atrial fibrillation. CNS: Fatigue; depression. GI: Abdominal pain. GU: UTI. METABOLIC: Hypertriglyceridemia; hyperkalemia; hypokalemia. RESPIRATORY: Upper respiratory tract infection; rhinitis; pharyngitis; coughing. OTHER: Arthralgia.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimesters). Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF), use may be associated with oliguria, progressive azotemia, acute renal failure, and death.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature in a tightly closed container.
  • Administer alone or in combination with other antihypertensives such as diuretic and calcium channel blocker.
  • Assess patient status and do not administer to patients with intravascular volume depletion until the condition has been corrected.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Monitor BP and pulse.
  • Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify the health care provider.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that eprosartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better.
  • Instruct patient not to increase or decrease the dosage.
  • Instruct patient that achievement of maximum BP reduction will usually take about 2 to 3 wk.
  • Instruct family and patient in BP and pulse measurement skills.
  • Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of eprosartan use prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning on becomming pregnant, or breastfeeding.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.